Cardiac mortality, diabetes mellitus, and multivessel disease in ST elevation myocardial infarction

Burgess, Sonya; Juergens, C.; Yang, Wesley; Shugman, I.; Idris, Hanan; Nguyen, T.; McLean, Alison; Leung, Melissa; Thomas, Liza; Robledo, Kristy; Mussap, C.; Lo, S.; French, John K.

doi:10.1016/j.ijcard.2020.08.021

Cited by 16 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Possible arguments would be that: (1) regarding age, STEMI patients with age ≥65 years were more likely to suffer from myocardial infarction, heart failure, cardiac death, etc 26–28 29 ; (3) inflammation participated in the progression of cardiovascular diseases, and CRP could reflect inflammation status 23,30,31 ; (4) STEMI patients with the multivessel disease were susceptible to MACE 32 ; therefore, abovementioned factors independently predicted MACE risk in STEMI patients. A subsequent prediction model performed by nomogram provided a reference for predicting the MACE risk at 1, 2, and 3 years; meanwhile, the ROC curve analysis suggested that this multivariate prediction model performed by nomogram may assist in MACE prediction for STEMI patients.…”

Section: Discussionmentioning

confidence: 99%

Serum VCAM‐1 and ICAM‐1 measurement assists for MACE risk estimation in ST‐segment elevation myocardial infarction patients

Liu

Peng

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Serum VCAM‐1 and ICAM‐1 measurement assists for MACE risk estimation in ST‐segment elevation myocardial infarction patients

Liu

Peng

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…During the considered study period (2010–2019), 146,798 patients hospitalized with a primary diagnosis of AMI (mean age 71 ± 13 years, 34% females, 47% STEMI; 26% patients with DM) were identified. Of them, 1,030 patients with DM were treated with GLP-1 RA/SGLT-2i (median time of drug administration prior to AMI 19 [ 6 – 27 ] months). Clinical characteristics and pharmacological therapy at hospital admission of the three groups before propensity score matching are reported in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Diabetes mellitus (DM) is a relevant risk factor and frequent comorbidity in patients hospitalized with acute myocardial infarction (AMI), with a prevalence of 20-30% [1][2][3]. Although current treatments have considerably improved survival in both DM and non-DM patients with AMI, the presence of DM still carries a higher risk of in-hospital mortality and major cardiovascular complications, doubling the case fatality rate [4][5][6][7]. This is likely due to multifactorial causes, including a higher number of comorbidities and burden of coronary artery disease, as well as an increase in inflammation and prothrombotic state [7].…”

Section: Introductionmentioning

confidence: 99%

Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction

Trombara

Cosentino

Bonomi

et al. 2023

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium glucose cotransporter-2 inhibitors (SGLT-2i) demonstrated cardiovascular and renal protection. Whether their benefits occur also during hospitalization for acute myocardial infarction (AMI) in patients with diabetes mellitus (DM) is not known. We evaluated in-hospital outcomes of patients hospitalized with AMI according to their chronic use of GLP-1 RA and/or SGLT-2i. Methods Using the health administrative databases of Lombardy, patients hospitalized with AMI from 2010 to 2019 were included. They were stratified according to DM status, then grouped into three cohorts using a propensity score matching: non-DM patients; DM patients treated with GLP-1 RA and/or SGLT-2i; DM patients not treated with GLP-1 RA/SGLT-2i. The primary endpoint of the study was the composite of in-hospital mortality, acute heart failure, and acute kidney injury requiring renal replacement therapy. Results We identified 146,798 patients hospitalized with AMI (mean age 71 ± 13 years, 34% females, 47% STEMI; 26% with DM). After matching, 3,090 AMI patients (1030 in each group) were included in the analysis. Overall, the primary endpoint rate was 16% (n = 502) and progressively increased from non-DM patients to DM patients treated with and without GLP-1 RA/SGLT-2i (13%, 16%, and 20%, respectively; P < 0.0001). Compared with non-DM patients, DM patients with GLP-1 RA/SGLT-2i had a 30% higher risk of the primary endpoint, while those not treated with GLP-1 RA/SGLT-2i had a 60% higher risk (P < 0.0001). Conclusion Chronic therapy with GLP-1 RA and/or SGLT-2i has a favorable impact on the clinical outcome of DM patients hospitalized with AMI.

show abstract

“…A multicenter trial has been conducted in patients with STEMI in which a total of 1335 patients were included among them the ratio of diabetics and non-diabetics were almost the same, 142 and 136, respectively. The overall rates of mortality and heart failure were most commonly seen in patients with diabetes mellitus as compared to non-diabetics 19.5% vs 14.3% [15].…”

Section: Acutementioning

confidence: 90%

In Hospital Frequency of Heart Failure in STEMI after Thrombolysis in Patient with Diabetes

Mueed

Rathi

Kazi

et al. 2021

JPRI

View full text Add to dashboard Cite

Objective: To determine the frequency of heart failure after thrombolysis in STEMI patients with diabetes mellitus. Methodology: Through a prospective study we have enrolled all the diabetic patients who presented with acute ST-Segment Elevation Myocardial Infarction (STEMI) having age more than 35 years and less than 70 years who underwent pharmacological revascularization both males and females were included in this study. Patients with previous history of revascularization, end stage kidney, liver or heart disease, known advanced valvular heart disease, pregnant women, and those who develop serious complication related to streptokinase were excluded from our study. Echocardiography was done immediately after thrombolysis then after 3 days and then before discharge of the patients to determine the frequency of heart failure. Baseline and clinical data were entered and analysed using SPSS and a chi square test and p-value ≤0.05 was considered as significant. Results: A total of 175 patients were finally analysed and most of them were males as compared to females, 63.42% (N = 111) vs. 36.57% (N = 64), respectively. Mean age and SD of the patients was 55.90±10.49 years and mean duration of DM was 12.95±8.40 years. The overall frequency of heart failure in patients with post-STEMI was 56% (N = 98) and their mean ejection fraction was 38.46±8.20%. Frequency of heart failure in diabetic post-STEMI thrombolysed patients was significantly observed higher with increased age, increased duration of diabetes mellitus, hypertension, and smoking (p≤0.05). Conclusion: High prevalence of heart failure was observed in diabetic patients admitted with acute STEMI and underwent thrombolysis. The burden is even higher in males having age more than 55 years.

show abstract

Cardiac mortality, diabetes mellitus, and multivessel disease in ST elevation myocardial infarction

Cited by 16 publications

References 30 publications

Serum VCAM‐1 and ICAM‐1 measurement assists for MACE risk estimation in ST‐segment elevation myocardial infarction patients

Serum VCAM‐1 and ICAM‐1 measurement assists for MACE risk estimation in ST‐segment elevation myocardial infarction patients

Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction

In Hospital Frequency of Heart Failure in STEMI after Thrombolysis in Patient with Diabetes

Contact Info

Product

Resources

About